Literature DB >> 8454184

Low-nutrient induction of abnormal chlamydial development: a novel component of chlamydial pathogenesis?

A M Coles1, D J Reynolds, A Harper, A Devitt, J H Pearce.   

Abstract

The intracellular development of chlamydiae in McCoy cells incubated in Eagle's minimal essential medium lacking all 13 amino acids was examined both by fluorescence and electron microscopy and by infectivity titration. Aberrant development occurred in almost all inclusions of strains of Chlamydia trachomatis and C. psittaci with the production of abnormal forms which differed in size, shape and internal structure from normal reticulate and elementary body forms. Detailed analysis of the response of C. trachomatis L2 strain 434 to graded reductions in amino acid level showed that infectivity was reduced and morphological abnormality increased as amino acid concentrations were lowered from 33 to 0% of amino acids present in minimal essential medium. Reversion of inclusions to normal and reappearance of infectious forms occurred on restoration of amino acids and further incubation. It is suggested that aberrant development may account for the presence in vivo of non-cultivable chlamydiae and that such development can arise via tryptophan deprivation mediated by local release of interferon gamma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8454184     DOI: 10.1111/j.1574-6968.1993.tb05958.x

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  43 in total

1.  Ultrastructural analysis of developmental events in Chlamydia pneumoniae-infected cells.

Authors:  K Wolf; E Fischer; T Hackstadt
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

2.  Identification of an antigen localized to an apparent septum within dividing chlamydiae.

Authors:  W J Brown; D D Rockey
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

3.  Cytokines induce indoleamine 2,3-dioxygenase expression in human atheroma-asociated cells: implications for persistent Chlamydophila pneumoniae infection.

Authors:  Jessica B Sakash; Gerald I Byrne; Andrew Lichtman; Peter Libby
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

4.  Interaction of Chlamydia trachomatis serovar L2 with the host autophagic pathway.

Authors:  Hesham M Al-Younes; Volker Brinkmann; Thomas F Meyer
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

Review 5.  Chlamydial persistence: beyond the biphasic paradigm.

Authors:  Richard J Hogan; Sarah A Mathews; Sanghamitra Mukhopadhyay; James T Summersgill; Peter Timms
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

6.  Beyond Tryptophan Synthase: Identification of Genes That Contribute to Chlamydia trachomatis Survival during Gamma Interferon-Induced Persistence and Reactivation.

Authors:  Matthew K Muramatsu; Julie A Brothwell; Barry D Stein; Timothy E Putman; Daniel D Rockey; David E Nelson
Journal:  Infect Immun       Date:  2016-09-19       Impact factor: 3.441

7.  Peptidomic analysis of human peripheral monocytes persistently infected by Chlamydia trachomatis.

Authors:  Birgit Krausse-Opatz; Annette Busmann; Harald Tammen; Christoph Menzel; Thomas Möhring; Nicolas Le Yondre; Cornelia Schmidt; Peter Schulz-Knappe; Henning Zeidler; Hartmut Selle; Lars Köhler
Journal:  Med Microbiol Immunol       Date:  2007-01-06       Impact factor: 3.402

8.  Chlamydia trachomatis persistence in vitro: an overview.

Authors:  Priscilla B Wyrick
Journal:  J Infect Dis       Date:  2010-06-15       Impact factor: 5.226

9.  Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro.

Authors:  U Dreses-Werringloer; I Padubrin; H Zeidler; L Köhler
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

10.  Reactivation of persistent Chlamydia trachomatis infection in cell culture.

Authors:  W L Beatty; R P Morrison; G I Byrne
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.